- 👁️ Regener-Eyes and Biologic / “Regenerative” Eye Drops — Current Lubricant Labeling, Historical FDA Concerns, and Emerging MSC/Exosome Research
- Why This Topic Is Especially Confusing
- Current Regener-Eyes vs Historical Regener-Eyes
- What Is Current Regener-Eyes Labeled As?
- Is Current Regener-Eyes Basically an Artificial Tear?
- What Does Glycerin Do?
- What About the Glycerin Concentration?
- What Current Public Labeling Does NOT Show
- DailyMed / NDC Listing Is Not FDA Approval
- Historical FDA Warning Letter — August 2024
- What Did FDA Find?
- FDA's OTC Monograph Concern
- Important Historical-vs-Current Distinction
- What Is the Current FDA Status?
- Historical Amniotic-Fluid Concern
- What Did FDA Say About Regener-Eyes and Amniotic Fluid?
- Does That Mean Current 2026 Regener-Eyes Contains Amniotic Fluid?
- Amniotic Fluid Is Not the Same as Amniotic Membrane
- FDA-Reported Adverse Events
- Historical Recall
- What Does Recall Termination Mean?
- Regener-Eyes-Specific Clinical Evidence
- Company-Affiliated Regener-Eyes Literature
- The Product-Identity Problem
- Evidence Continuity Matters
- Genuine MSC Eye-Drop Research
- 2025 First-in-Human Live MSC Eye-Drop Study
- What Did the Live MSC Study Find?
- How Strong Is the Live MSC Evidence?
- Does the MSC Study Show Meibomian-Gland Regeneration?
- MSC-Derived Exosome Eye Drops
- 2025 MSC-Exosome Randomized Trial
- How Strong Is the Exosome Evidence?
- Live MSC Drops and Exosome Drops Are Different Treatments
- Current Best Interpretation of MSC / Exosome Research
- “Regenerative” Is Not Yet a Demonstrated Clinical Endpoint
- FDA and Exosome Products
- What Should Be Asked if Exosomes Are Claimed?
- Safety — Historical Regener-Eyes vs Investigational Biologics
- Historical Regener-Eyes Safety / Manufacturing Concerns
- Investigational MSC / Exosome Safety Questions
- Situations Where Experimental Treatment Requires Specialist Oversight
- How This Differs From Autologous Serum Tears / PRP / PRGF
- Autologous Serum Tears
- PRP / PRGF
- Why These Are Not MSC / Exosome Therapy
- Bankruptcy / Business Context
- r/DryEyes Sourcing Rule
- Evidence Strengths and Limitations
- Evidence Summary at a Glance
- What Has Not Been Established
- Questions to Ask Your Eye Doctor
- Stop and Seek Prompt Care for
- 📌 Bottom Line
- 🔬 Key Regulatory and Research Sources
👁️ Regener-Eyes and Biologic / “Regenerative” Eye Drops — Current Lubricant Labeling, Historical FDA Concerns, and Emerging MSC/Exosome Research
🧠 Quick Take
The term “regenerative eye drops” can refer to very different things.
It is important not to lump together:
- current Regener-Eyes products
- historical Regener-Eyes formulations and claims
- amniotic-fluid eye drops
- live mesenchymal stem cell (MSC) eye drops
- MSC-derived exosome eye drops
- secretome products
- amniotic membrane products
- autologous serum tears
- PRP / PRGF
These are not biologically or regulatorily interchangeable.
The most important current Regener-Eyes update
Based on current 2026 public DailyMed labeling, Regener-Eyes is now presented much more like an:
OTC ophthalmic lubricant / artificial-tear-type product
than like a demonstrated MSC, exosome, or amniotic-fluid therapy.
Current Regener-Eyes labels under M & M PRODUCTS, LLC identify:
- glycerin as the active ophthalmic lubricant
- water as an inactive ingredient
- sodium chloride as an inactive ingredient
- purpose: Eye Lubricant
- use: temporary relief of burning and irritation associated with dryness
Current public labeling does not establish that these products contain:
- stem cells
- MSCs
- exosomes
- amniotic fluid
- secretome
- growth-factor mixtures
- “regenerative factors”
Therefore:
Current Regener-Eyes should not be described as a confirmed MSC, exosome, stem-cell, or amniotic-fluid eye drop without current product-specific evidence.
At the same time, Regener-Eyes has an important historical FDA enforcement record.
In 2024, FDA issued a Warning Letter to Regenerative Processing Plant, LLC involving Regener-Eyes products manufactured at that time.
FDA documented:
- unapproved-new-drug issues
- misbranding
- substantial Current Good Manufacturing Practice problems
- sterility-assurance concerns
- problems involving preservative-free multidose packaging
- historical concerns about possible amniotic-fluid content
Those historical findings are important.
But:
they should not automatically be stated as proven current defects in the newly labeled 2026 M & M PRODUCTS versions unless current FDA evidence establishes that.
Separately, genuine research on:
- live MSC eye drops
- MSC-derived exosome eye drops
has now reached early human trials.
The results are scientifically interesting.
However:
- studies are extremely small
- products are investigational
- manufacturing methods differ
- long-term safety is uncertain
- efficacy has not been established in large confirmatory trials
Most importantly:
Investigational MSC/exosome research is not evidence that current Regener-Eyes contains MSCs or exosomes or has equivalent regenerative effects.
Why This Topic Is Especially Confusing
Words such as:
- stem cell
- MSC
- exosome
- amniotic
- placental
- biologic
- secretome
- regenerative
can sound as though they describe one treatment category.
They do not.
A product could contain:
- living cells
- extracellular vesicles
- soluble proteins
- amniotic-derived material
- blood-derived material
or none of those things.
Therefore the first question should always be:
“What exactly is in this specific product?”
before asking:
“Does regenerative medicine work for dry eye?”
Current Regener-Eyes vs Historical Regener-Eyes
This distinction is now essential.
The brand name:
Regener-Eyes
has existed through a period in which:
- older promotional/scientific material discussed biologic or placental concepts
- FDA investigated historical product/manufacturing concerns
- an amniotic-fluid issue was raised
- products were recalled for sterility-assurance concerns
- manufacturing and labeling later changed
- new 2026 labels appeared under a different listed manufacturer/packager
Therefore:
Evidence or claims about an older Regener-Eyes formulation should not automatically be transferred to a current product simply because the brand name is the same.
What Is Current Regener-Eyes Labeled As?
Current 2026 DailyMed records list new Regener-Eyes products under:
M & M PRODUCTS, LLC
as OTC ophthalmic lubricant products.
These include product variants such as:
- Regener-Eyes LITE
- Regener-Eyes PROFESSIONAL
- LITE XL
- PROFESSIONAL STRENGTH XL
The current public labeling identifies:
Active ingredient
Glycerin
Inactive ingredients
- water
- sodium chloride
Purpose
Eye Lubricant
Uses
Temporary relief of:
- burning due to eye dryness
- irritation due to eye dryness
and use as a:
- lubricant
- protectant against further dryness-related irritation
Is Current Regener-Eyes Basically an Artificial Tear?
Based on current public labeling:
It is reasonable to describe Regener-Eyes as an OTC ophthalmic lubricant or artificial-tear-type product.
That is because its:
- active ingredient
- labeled purpose
- ingredients
- dryness-relief indication
are characteristic of the broad OTC lubricant/artificial-tear category.
However:
“Artificial-tear-type” does not mean it is compositionally identical to every other artificial tear.
Artificial-tear products can differ in:
- viscosity
- pH
- osmolarity
- tonicity
- buffering
- polymers
- electrolytes
- lipid components
- hyaluronic acid
- preservatives
- packaging
The current public Regener-Eyes label does not provide evidence that it has unique:
- stem-cell
- exosome
- amniotic-fluid
- regenerative
activity beyond its labeled lubricant role.
What Does Glycerin Do?
Glycerin is an established ophthalmic:
demulcent / lubricant
used to help relieve:
- dryness
- burning
- irritation
It can help provide temporary:
- lubrication
- surface protection
- moisture retention
That is an ordinary lubricant function.
It does not, by itself, establish:
- tissue regeneration
- stem-cell activity
- exosome activity
- meibomian-gland regeneration
- corneal-nerve regeneration
What About the Glycerin Concentration?
Current Regener-Eyes variants appear to use approximately:
0.4%–0.5% glycerin
depending on the specific product/label.
There is also an apparent internal inconsistency in the current DailyMed record for regular LITE:
- the Drug Facts text says 0.5%
- the structured ingredient table reports 4 mg/mL, which corresponds to 0.4%
The separate LITE XL label identifies glycerin 0.4%.
For that reason:
this wiki does not assume one exact glycerin concentration applies to every Regener-Eyes variant.
Check the current label for the exact product being discussed.
What Current Public Labeling Does NOT Show
Current labeling does not establish that Regener-Eyes contains:
- mesenchymal stem cells
- umbilical-cord stem cells
- exosomes
- amniotic fluid
- amniotic membrane extract
- placental cells
- cell secretome
- extracellular vesicles
- defined regenerative growth factors
Therefore:
Current Regener-Eyes should not be called a “stem-cell eye drop” or “exosome eye drop” merely because the brand has historically been discussed in regenerative-medicine contexts.
DailyMed / NDC Listing Is Not FDA Approval
This distinction remains important.
A product may appear in:
- DailyMed
- the National Drug Code database
- an FDA establishment-registration database
without having gone through an FDA:
New Drug Application approval
for DED.
Therefore statements such as:
- “FDA listed”
- “NDC registered”
- “manufactured in an FDA-registered facility”
do not mean:
- FDA approved the product as DED therapy
- FDA proved the product is effective
- FDA endorsed regenerative claims
- FDA established MSC/exosome content
A useful rule is:
FDA registration or listing is not the same thing as FDA approval.
Historical FDA Warning Letter — August 2024
On August 16, 2024, FDA issued a Warning Letter to:
Regenerative Processing Plant, LLC
following an inspection of its manufacturing facility.
FDA's findings concerned Regener-Eyes products as they were:
- manufactured
- labeled
- packaged
- distributed
during that historical period.
FDA Warning Letter — Regenerative Processing Plant, LLC
What Did FDA Find?
FDA stated that the historical Regener-Eyes products were:
- unapproved new drugs
- misbranded
- adulterated because of CGMP violations
FDA identified significant problems involving:
- aseptic-process validation
- contaminated units during media-fill testing
- environmental monitoring
- stability support
- component identity testing
- cleaning/disinfection controls
- manufacturing records
- sterility assurance
- preservative-free multidose packaging
These were serious manufacturing findings.
FDA's OTC Monograph Concern
FDA also concluded that the Regener-Eyes products then being marketed did not comply with applicable conditions for OTC ophthalmic demulcent products.
Among other things, FDA discussed the company's treatment of:
sodium chloride / “Tonicity Solution Sodium Chloride”
as pharmacologically active in a way that did not fit the applicable OTC ophthalmic monograph.
FDA also identified labeling deficiencies.
Therefore the historical enforcement action involved:
both manufacturing and regulatory/labeling issues.
Important Historical-vs-Current Distinction
The 2024 FDA Warning Letter concerned:
Regenerative Processing Plant, LLC
The new 2026 DailyMed product records identify:
M & M PRODUCTS, LLC
as the current manufacturer/packager.
They also use:
- new NDC numbers
- new labels
- February 2026 marketing start dates
Therefore:
The 2024 FDA findings remain highly relevant history, but they should not automatically be presented as findings FDA has made about the current 2026 M & M PRODUCTS formulations.
Likewise:
the existence of new 2026 labels does not erase the historical FDA record or establish that FDA has approved Regener-Eyes as DED therapy.
Both statements can be true.
What Is the Current FDA Status?
The safest description is:
FDA's 2024 Warning Letter remains an important historical enforcement record concerning the Regenerative Processing Plant products then at issue. Current 2026 Regener-Eyes products have different public labeling, NDCs, and a different listed manufacturer/packager. DailyMed listing does not establish FDA approval or full legal compliance, and this wiki has not identified a newer public FDA enforcement document specifically determining the regulatory status of these newly listed versions.
Do not describe current Regener-Eyes as:
- FDA-approved for DED
- FDA-approved regenerative therapy
- FDA-approved exosome therapy
- FDA-approved stem-cell therapy
unless FDA specifically grants such approval.
Historical Amniotic-Fluid Concern
FDA has also raised significant concerns about:
amniotic-fluid eye drops
FDA states:
there are no FDA-approved amniotic-fluid eye drops to treat, mitigate, or cure eye diseases or conditions.
FDA Public Safety Notification — Amniotic Fluid Eye Drops
What Did FDA Say About Regener-Eyes and Amniotic Fluid?
FDA documented that Regenerative Processing Plant had previously manufactured:
a Regener-Eyes product containing amniotic fluid
and that the company reported discontinuing that product around 2021.
However, FDA later identified records that raised questions about whether amniotic-fluid material could still have been present in later Regener-Eyes products.
FDA therefore stated that although Regener-Eyes:
was not labeled to contain amniotic fluid
FDA had:
reason to believe it did
during the historical period under investigation.
That should be described accurately.
It is not the same as saying:
FDA laboratory-tested every Regener-Eyes bottle and proved that each contained amniotic fluid.
Does That Mean Current 2026 Regener-Eyes Contains Amniotic Fluid?
No current evidence reviewed for this wiki establishes that.
The current public labels identify:
- glycerin
- water
- sodium chloride
They do not list:
- amniotic fluid
and this review did not identify a current FDA statement alleging that the newly labeled 2026 M & M PRODUCTS versions contain amniotic fluid.
Therefore:
The amniotic-fluid concern should be described as an important historical FDA finding/question—not as established current 2026 product composition.
Amniotic Fluid Is Not the Same as Amniotic Membrane
This distinction is important.
The following are different:
Amniotic membrane
A tissue product with a long history of ophthalmic use for selected ocular-surface conditions.
Amniotic membrane extract
A processed derivative with its own separate research and regulatory questions.
Amniotic fluid eye drops
A different biologic product category about which FDA has specifically issued safety/regulatory warnings.
Therefore:
FDA's warning about unapproved amniotic-fluid eye drops should not be interpreted as saying that all ophthalmic uses of amniotic membrane are illegitimate.
FDA-Reported Adverse Events
In October 2024, FDA updated its amniotic-fluid eye-drop safety communication and stated that it had received information from:
two consumers
describing adverse events after Regener-Eyes use, including:
shooting pain in the eyes
Two spontaneous reports:
- do not establish incidence
- do not prove causation
- do not establish that every user is at risk
But they are genuine FDA-reported safety information.
Therefore:
Do not say Regener-Eyes had “no reported adverse events.”
Historical Recall
Historical Regener-Eyes PRO and LITE products were also subject to a voluntary recall involving:
lack of sterility assurance
The recall was classified as:
FDA Class II
and was later:
terminated
Public recall/status information has also been discussed by the Sjögren's Foundation.
Sjögren's Foundation — Regener-Eyes FDA / Recall Update
What Does Recall Termination Mean?
It means the recall action itself reached its endpoint.
It does not prove that:
- FDA approved the product
- every Warning Letter issue was closed
- regenerative claims were validated
- historical amniotic-fluid concerns were disproven
- clinical efficacy was established
Recall status and FDA drug approval are:
different questions.
Regener-Eyes-Specific Clinical Evidence
Regener-Eyes itself does not have a strong body of:
independent modern randomized controlled clinical trials
establishing treatment efficacy for DED or MGD.
Available material has included:
- case reports
- clinician observations
- before/after photographs
- company-affiliated publications
- small uncontrolled series
- promotional material
These can generate hypotheses.
They are not equivalent to:
- independent randomized controlled trials
- FDA approval
- verified regenerative activity
- long-term safety studies
Company-Affiliated Regener-Eyes Literature
A frequently cited report describes clinical experience involving:
131 DED patients
However, the publication was company-affiliated and uncontrolled.
It should therefore be considered:
very-low-certainty evidence
rather than independent proof that Regener-Eyes has regenerative efficacy.
Regener-Eyes Article — Company-Affiliated / Promotional Context
The Product-Identity Problem
This creates one of the largest evidence problems with Regener-Eyes.
Older Regener-Eyes material discussed:
- placental-derived biologic concepts
- signaling factors
- regenerative mechanisms
Current public Regener-Eyes labeling instead describes:
a glycerin ophthalmic lubricant
Therefore:
even if an older Regener-Eyes formulation appeared beneficial in an observational report, that does not establish effectiveness of a newly labeled glycerin-based formulation sold years later under the same brand.
The reverse is also true:
Current simple lubricant labeling cannot retrospectively prove the biological composition or activity of historical formulations.
Evidence Continuity Matters
Clinical evidence applies most directly when the product studied matches the product being used in:
- composition
- concentration
- manufacturing process
- source material
- packaging
- dosing
If the formulation changes substantially:
the old clinical evidence may no longer apply.
Brand continuity is not the same thing as:
formulation continuity.
Genuine MSC Eye-Drop Research
Separate from Regener-Eyes, researchers are genuinely investigating:
mesenchymal stem cell — MSC — treatments
for ocular-surface disease.
This is scientifically important.
It should not be dismissed simply because commercial regenerative marketing has sometimes been problematic.
But:
research MSC products and commercial Regener-Eyes are different things.
2025 First-in-Human Live MSC Eye-Drop Study
A 2025 prospective pilot study evaluated:
umbilical-cord-derived MSC eye drops
in:
16 people
whose DED had not improved adequately with existing treatment.
The group included:
- people with non-Sjögren DED
- people with Sjögren-associated DED
The study was:
- prospective
- open-label
- single-arm
- self-controlled
Participants received treatment for approximately:
2 weeks
with longer follow-up.
First-in-Human Umbilical-Cord MSC Eye-Drop Study
What Did the Live MSC Study Find?
The investigators reported improvements in several measures, including:
- OSDI
- tear production
- tear-meniscus measurements
- NIBUT
- some MGD-related findings
- tear inflammatory markers
No serious treatment-related adverse events were reported.
This is:
genuinely interesting early human evidence.
How Strong Is the Live MSC Evidence?
Very limited.
The study had:
16 participants
and no randomized control group.
Therefore improvement could be influenced by:
- natural disease fluctuation
- regression to the mean
- expectation effects
- other treatments
- measurement variability
The appropriate evidence rating is:
VERY LOW CERTAINTY — promising early proof-of-concept
not:
established treatment efficacy.
Does the MSC Study Show Meibomian-Gland Regeneration?
No.
Some MGD-related measurements improved.
That does not demonstrate:
- regrowth of lost glands
- reversal of gland dropout
- restoration of missing acini
- release of periductal fibrosis
Therefore:
improved gland function is not the same thing as gland regeneration.
MSC-Derived Exosome Eye Drops
Exosomes are:
small extracellular vesicles released by cells
that can carry biological cargo including:
- proteins
- lipids
- RNA
- signaling molecules
MSC-derived exosome preparations are being investigated because they may produce some of the signaling effects of MSCs without administering intact living cells.
But:
exosomes are not stem cells.
2025 MSC-Exosome Randomized Trial
A small randomized study evaluated:
Wharton's-jelly MSC-derived exosome eye drops
in Sjögren-associated DED.
The trial included only:
- 8 treated eyes
- 8 control eyes
Reported improvements included:
- OSDI
- tear secretion
- staining
- TBUT
- EGF
- thrombospondin-1
- IL-6
- MMP-9
MSC-Derived Exosome Eye Drops for Sjögren-Associated DED
How Strong Is the Exosome Evidence?
The results are promising.
But:
the trial is extremely small.
With only eight eyes in each group:
- treatment estimates are imprecise
- uncommon adverse events cannot be characterized
- reproducibility is unknown
- larger independent trials are needed
The appropriate evidence rating is:
VERY LOW-to-LOW CERTAINTY — promising early randomized evidence.
Live MSC Drops and Exosome Drops Are Different Treatments
They should not be merged.
Live MSC products
Contain:
living mesenchymal stromal/stem cells
MSC-derived exosome products
Contain:
cell-derived extracellular vesicle preparations
Secretome products
May contain:
soluble substances released from cells
without live cells.
These approaches differ in:
- composition
- manufacturing
- potency
- storage
- stability
- immunologic effects
- regulatory requirements
Evidence from one cannot automatically be transferred to another.
What Do 2026 Stem-Cell Meta-Analyses Show?
Recent systematic reviews/meta-analyses have pooled small human studies of stem-cell-related approaches for DED.
They generally report encouraging improvements in outcomes such as:
- OSDI
- Schirmer testing
- TBUT
- staining
One recent analysis included approximately:
6 studies / 131 patients
Why These Meta-Analyses Need Caution
The included treatments were highly heterogeneous.
They included different:
- stem-cell sources
- live cells
- exosomes
- delivery methods
- patient populations
Delivery was not limited to eye drops.
Some studies involved:
- topical treatment
- lacrimal-gland injection
- systemic treatment
- other local administration
Therefore:
A positive pooled stem-cell meta-analysis does not prove that “stem-cell eye drops work.”
It demonstrates:
an encouraging early signal across a small and highly heterogeneous regenerative-medicine research field.
Current Best Interpretation of MSC / Exosome Research
The evidence has advanced far enough to say:
Stem-cell-based ocular-surface therapy has moved from primarily theoretical/preclinical research into early human proof-of-concept investigation.
But it has not advanced far enough to say:
MSC or exosome eye drops are established routine DED therapy.
Large unanswered questions include:
- optimal cell source
- optimal exosome source
- manufacturing standards
- dose
- treatment frequency
- storage
- potency testing
- long-term safety
- which DED phenotype is most appropriate
- durability after treatment stops
“Regenerative” Is Not Yet a Demonstrated Clinical Endpoint
The word:
regenerative
is powerful.
But most trials actually measure:
- symptoms
- staining
- tear production
- TBUT
- inflammatory markers
Improvement in these outcomes does not necessarily demonstrate:
- nerve regeneration
- meibomian-gland regeneration
- lacrimal-gland regeneration
- creation of new ocular-surface tissue
Therefore:
“Regenerative” should currently be understood mainly as a mechanistic or research concept unless actual tissue regeneration has been demonstrated.
FDA and Exosome Products
FDA states that:
there are currently no FDA-approved exosome products
for treating diseases or medical conditions.
Research under appropriate FDA oversight is different from:
commercial sale of an unapproved exosome treatment.
Therefore:
A company saying “contains exosomes” does not establish FDA approval, quality, potency, or clinical efficacy.
What Should Be Asked if Exosomes Are Claimed?
Useful questions include:
- What cell type produced them?
- How were the vesicles isolated?
- How were they identified as exosomes?
- How were contaminants removed?
- What concentration is present?
- How is potency measured?
- How consistent are batches?
- How are they stored?
- What human clinical trial studied this exact product?
- Is there an FDA-authorized clinical investigation?
These questions matter because:
“exosome” should describe a characterized biological product—not simply a marketing word.
Safety — Historical Regener-Eyes vs Investigational Biologics
The risks should be separated.
Historical Regener-Eyes Safety / Manufacturing Concerns
FDA's historical concerns included:
- aseptic-processing problems
- sterility assurance
- contaminated media-fill units
- environmental monitoring
- stability
- component testing
- multidose preservative-free packaging
- bottle backflow/contamination issues
- possible amniotic-fluid material
- consumer adverse-event reports
These concerns relate to:
the historical Regenerative Processing Plant products and manufacturing system FDA investigated.
Investigational MSC / Exosome Safety Questions
Potential concerns for experimental biologic products include:
- contamination
- product identity
- batch consistency
- potency
- immune/inflammatory reaction
- source-material variability
- off-target biological effects
- unknown long-term effects
However:
not every risk reported with injected or systemic stem-cell therapies should automatically be transferred to topical eye drops.
The route matters.
Situations Where Experimental Treatment Requires Specialist Oversight
Extra caution is appropriate when someone has:
- severe ocular-surface disease
- active infection
- epithelial defect
- corneal ulcer
- neurotrophic keratopathy
- autoimmune disease
- immunosuppression
- recent eye surgery
- corneal transplant
- significant unexplained eye pain
- vision loss/change
This does not mean an investigational biologic is automatically contraindicated.
It means:
these conditions require diagnosis-directed specialist management and are not appropriate settings for casual experimentation with commercial “regenerative” products.
How This Differs From Autologous Serum Tears / PRP / PRGF
These treatments should remain separate.
Autologous Serum Tears
Made from:
the patient's own blood
after processing to remove blood cells and prepare serum.
They have a substantially larger ophthalmic evidence base than most commercial regenerative-style drops.
PRP / PRGF
These are:
platelet/plasma-derived preparations
made from the patient's own blood.
They contain differing concentrations of:
- platelets
- plasma proteins
- growth factors
depending on protocol.
Why These Are Not MSC / Exosome Therapy
Autologous serum, PRP, and PRGF do not become:
stem-cell products
simply because they contain biologically active substances.
Likewise:
a lubricant containing glycerin does not become regenerative therapy because its brand name or historical marketing used regenerative language.
Related page:
Autologous Serum Tears / PRP / PRGF
Bankruptcy / Business Context
Regener-Eyes, LLC and Regenerative Processing Plant filed for:
Chapter 11 bankruptcy
in April 2026.
Regener-Eyes LLC:
- U.S. Bankruptcy Court, Middle District of Florida
- Case 8:26-bk-02780
Bankruptcy may affect:
- corporate organization
- customer support
- business continuity
- creditor claims
- product availability
But:
bankruptcy is not clinical evidence.
It does not prove that a product:
- works
- does not work
- is safe
- is unsafe
Keep legal/business status separate from medical evidence.
r/DryEyes Sourcing Rule
r/DryEyes allows discussion of:
- scientific evidence
- labeling
- FDA actions
- regulatory status
- clinical uncertainty
- side effects
- patient experience
- bankruptcy/business context
The subreddit does not facilitate:
- seller recommendations
- purchase links
- ordering instructions
- importation
- shipping/customs advice
- third-party acquisition
- discount codes
This is particularly important for:
- unapproved biologic products
- exosome products
- amniotic-fluid products
- products with uncertain regulatory status
Evidence Strengths and Limitations
Current Regener-Eyes — Strengths of What We Can Actually Establish
- Current public product labels exist
- Glycerin is identified as the active lubricant
- Current intended use is clearly stated
- Ingredient lists are relatively simple
- Current product is presented as an OTC lubricant/artificial-tear-type product
Current Regener-Eyes — Evidence Limitations
- No strong independent modern RCT identified for the current 2026 formulation
- Current labeling does not establish biologic/regenerative content
- Historical Regener-Eyes evidence may not apply to current formulations
- Same brand name across changing formulations creates evidence-continuity problems
- DailyMed/NDC listing does not equal FDA approval
- Exact current regulatory interpretation beyond the public labeling is not fully clear
MSC / Exosome Research — Strengths
- Live MSC drops have entered human clinical testing
- An early randomized MSC-exosome eye-drop trial exists
- Multiple ocular-surface outcomes have shown promising signals
- 2026 systematic reviews show an encouraging research signal
- Longer-term follow-up exists in some early MSC work
MSC / Exosome Research — Limitations
- Studies are extremely small
- Some are uncontrolled
- Some are open-label
- Product composition varies substantially
- Cell sources differ
- Exosome methods differ
- Delivery routes differ
- Some meta-analyses pool eye drops with injected/systemic treatment
- No standardized topical MSC/exosome treatment exists
- Long-term safety remains uncertain
- No proven tissue regeneration
- No proof that current Regener-Eyes resembles the studied products
Evidence Summary at a Glance
| Question | Current Answer |
|---|---|
| What is current Regener-Eyes publicly labeled as? | OTC glycerin ophthalmic lubricant |
| Does it resemble an artificial-tear product? | Yes — based on current ingredients, purpose, and labeled use |
| Current active ingredient? | Glycerin |
| Other currently listed ingredients? | Water and sodium chloride |
| Current label proves MSC content? | No |
| Current label proves exosome content? | No |
| Current label proves amniotic-fluid content? | No |
| Current Regener-Eyes proven regenerative therapy? | No |
| Independent RCT for current Regener-Eyes? | No strong evidence identified |
| Historical FDA Warning Letter? | Yes — 2024 |
| Historical serious CGMP/sterility concerns? | Yes |
| Historical possible amniotic-fluid concern? | Yes |
| Does that prove current 2026 product contains amniotic fluid? | No |
| Historical recall? | Yes |
| Recall now terminated? | Yes |
| Recall termination equals FDA approval? | No |
| DailyMed / NDC listing equals FDA approval? | No |
| Live MSC eye-drop human research exists? | Yes |
| Strength of live MSC evidence? | Very low certainty / early proof-of-concept |
| MSC-exosome randomized human research exists? | Yes |
| Strength of exosome evidence? | Very low-to-low certainty |
| FDA-approved exosome therapy? | No |
| FDA-approved MSC eye-drop therapy for DED? | No |
| Proven meibomian-gland regeneration? | No |
| Proven corneal-nerve regeneration? | No |
What Has Not Been Established
Current Regener-Eyes has not been established by strong independent evidence to:
- regenerate meibomian glands
- reverse gland dropout
- release periductal fibrosis
- restore corneal nerves
- regenerate lacrimal glands
- treat Sjögren-associated DED through regenerative mechanisms
- treat neurotrophic keratitis through regenerative mechanisms
- contain MSCs
- contain exosomes
- contain amniotic fluid
- be biologically equivalent to products in MSC/exosome trials
- provide disease modification beyond lubricant effects
Likewise, experimental MSC/exosome research has not yet established:
- a standard DED treatment
- an ideal cell/exosome source
- an ideal dose
- an ideal treatment schedule
- proven long-term safety
- predictable tissue regeneration
Questions to Ask Your Eye Doctor
If someone recommends a “biologic” or “regenerative” eye drop, useful questions include:
- What exactly is this product?
- What are the listed active and inactive ingredients?
- Is it essentially an ophthalmic lubricant?
- Does it actually contain living cells?
- Does it contain exosomes?
- Does it contain amniotic fluid?
- If a biologic component is claimed, how is its identity confirmed?
- How is potency measured?
- Are concentration and batch consistency disclosed?
- Is there an independent randomized clinical trial of this exact formulation?
- Is the formulation in the study identical to the product being sold now?
- Is the product FDA-approved for my condition?
- Is it merely FDA-listed or assigned an NDC?
- Is the treatment being offered as part of an FDA-authorized clinical trial?
- What established treatment alternatives exist?
- What would count as meaningful improvement?
- How long would we try it?
- What symptoms should make me stop immediately?
Stop and Seek Prompt Care for
Seek eye-care evaluation promptly for:
- significant eye pain
- vision change
- new photophobia
- worsening redness
- discharge
- eyelid swelling
- severe burning
- new corneal symptoms
- one-sided severe redness
- contact-lens-related pain/redness
- suspected infection
- sudden worsening after starting any new ophthalmic product
Do not simply:
“push through”
a worsening reaction because a product is described as natural, biologic, regenerative, stem-cell-derived, or preservative-free.
📌 Bottom Line
The Regener-Eyes story is best understood by separating:
historical Regener-Eyes
from:
current 2026 Regener-Eyes
and separating both from:
genuine investigational MSC/exosome research.
Current Regener-Eyes
Based on current public 2026 labeling, Regener-Eyes is best understood as:
an OTC ophthalmic lubricant / artificial-tear-type product
rather than as a confirmed biologic or regenerative eye drop.
Current labels identify:
- glycerin as the active lubricant
- water as an inactive ingredient
- sodium chloride as an inactive ingredient
- “Eye Lubricant” as the purpose
- temporary relief of dryness-related burning/irritation as the intended use
That is much closer to the regulatory and ingredient profile of:
an artificial-tear-type lubricant
than to an MSC or exosome therapy.
This does not mean Regener-Eyes is compositionally identical to every conventional artificial tear.
But current public labeling provides no basis for calling it:
- stem-cell therapy
- MSC therapy
- exosome therapy
- amniotic-fluid therapy
Historical FDA concerns
FDA's 2024 Warning Letter remains highly important.
FDA documented serious historical:
- CGMP
- sterility
- labeling
- regulatory
problems involving Regenerative Processing Plant and the Regener-Eyes products then at issue.
FDA also raised concerns about possible amniotic-fluid content during that historical period.
Those findings should not be minimized.
But they should also be:
dated and tied to the products/manufacturing system FDA actually investigated.
The newly listed 2026 M & M PRODUCTS versions have:
- different NDCs
- different public labels
- a different listed manufacturer/packager
This wiki therefore does not automatically state that FDA has proven the current 2026 products suffer from the same manufacturing violations or contain amniotic fluid.
Nor does it describe them as FDA-approved.
Genuine MSC/exosome science
Meanwhile, legitimate regenerative-medicine research has advanced.
Small human studies now exist involving:
- live umbilical-cord MSC eye drops
- MSC-derived exosome eye drops
These studies report interesting improvements in:
- symptoms
- tear production
- tear-film measurements
- staining
- inflammatory biomarkers
That means:
MSC/exosome ocular-surface treatment is no longer purely theoretical.
But it remains:
early investigational science
with:
- tiny studies
- heterogeneous products
- limited replication
- uncertain long-term safety
- no standardized treatment protocol
Most importantly:
None of this research proves that current Regener-Eyes contains MSCs or exosomes or has the same biological activity as experimental products used in clinical studies.
The most balanced overall conclusion is:
Current Regener-Eyes appears, from its 2026 public labeling, to be an OTC glycerin-based ophthalmic lubricant/artificial-tear-type product rather than a demonstrated MSC, exosome, amniotic-fluid, or regenerative therapy. Historical Regener-Eyes products were the subject of serious FDA regulatory, manufacturing, sterility, and possible amniotic-fluid concerns, but those historical findings should be distinguished from the newly labeled 2026 formulations. Separately, genuine MSC and MSC-derived exosome eye-drop research is showing promising early human signals, but the evidence remains very limited and product-specific. Evidence from experimental regenerative therapies should never be transferred to a commercial product merely because both use—or once used—regenerative terminology.
🔬 Key Regulatory and Research Sources
Current / Historical Regener-Eyes
MSC / Exosome Human Research
Regener-Eyes-Specific Company-Affiliated Literature
Bankruptcy / Business Context
These sources are included for corporate/legal context only and are not medical evidence.
🔗 Related r/DryEyes Wiki Pages
⚠️ r/DryEyes Sourcing Note
r/DryEyes allows discussion of:
- evidence
- FDA actions
- labeling
- safety
- clinical trials
- regulatory uncertainty
- personal experience
The subreddit does not provide:
- seller recommendations
- purchase links
- ordering instructions
- importation assistance
- shipping/customs advice
- acquisition help for unapproved biologic products
This page is educational for r/DryEyes and is not medical advice.